🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Remo Panaccione

University of Calgary

ORCID: 0000-0002-5247-940X

Biochemistry, Genetics and Molecular BiologyMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease”.

Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

Gastroenterology(2020)10.1053/j.gastro.2020.03.039

N/A

5.7DataRank · unranked

240 citations

Clara Yzet, Peter Bossuyt, Filip J. Baert, Thomas Vanasek, Geert D’Haens +34 more

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data

Inflammatory Bowel Diseases(2023)10.1093/ibd/izad016

N/A

0.761DataRank · unranked

25 citations

Jacinda Tran, Geert D’Haens, David T. Rubin, Nobuo Aoyama, Wen Zhou +5 more

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

The Lancet. Gastroenterology & hepatology(2025)10.1016/s2468-1253(25)00017-2

N/A

0.690DataRank · unranked

22 citations

Séverine Vermeire, Silvio Danese, Peter Higgins, Gary R. Lichtenstein, Hiroshi Nakase +12 more

Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies

Journal of Crohn s and Colitis(2024)10.1093/ecco-jcc/jjae164

N/A

0.303DataRank · unranked

5 citations

Marc Ferrante, Remo Panaccione, Brian G. Feagan, О. Б. Щукина, Vipul Jairath +11 more

Vedolizumab for the treatment of ulcerative colitis

Expert Opinion on Biological Therapy(2016)10.1517/14712598.2016.1121231

N/A

0.165DataRank · unranked

2 citations

Brian Bressler, Remo Panaccione, Neal Shahidi

Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis

The Lancet. Gastroenterology & hepatology(2021)10.1016/s2468-1253(21)00312-5

N/A

0DataRank · unranked

298 citations

Mohammad Hassan Murad, Mathurin Fuméry, Rocío Sedaño, Vipul Jairath, Remo Panaccione +3 more

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

Clinical Gastroenterology and Hepatology(2020)10.1016/j.cgh.2020.07.012

N/A

0DataRank · unranked

88 citations

Paulo Gustavo Kotze, Alice Burgevin, Willam Tan, Alison T. Jess, Pei-Shun Li +7 more